The National Amyotrophic Lateral Sclerosis (ALS) Registry

Vinicius C. Antao, MSc, MD, PhD
D. Kevin Horton, MSPH, DrPH

Editor’s Note: As part of our continuing effort to highlight innovative approaches to improving the health and environment of communities, the Journal is pleased to bring back the bimonthly column from the U.S. Agency for Toxic Substances and Disease Registry (ATSDR). The ATSDR, based in Atlanta, Georgia, is a federal public health agency of the U.S. Department of Health and Human Services and shares a common office of the Director with the National Center for Environmental Health at the Centers for Disease Control and Prevention (CDC). ATSDR serves the public by using the best science, taking responsive public health actions, and providing trusted health information to prevent harmful exposures and diseases related to toxic substances.

The purpose of this column is to inform readers of ATSDR’s activities and initiatives to better understand the relationship between exposure to hazardous substances in the environment and their impact on human health and how to protect public health. We believe that the column will provide a valuable resource to our readership by helping to make known the considerable resources and expertise that ATSDR has available to assist communities, states, and others to assure good environmental health practice for all is served.

The conclusions of this article are those of the author(s) and do not necessarily represent the views of ATSDR, CDC, or the U.S. Department of Health and Human Services.

Vinicius Antao is the registries team leader in the Environmental Health Surveillance Branch within the Division of Toxicology and Human Health Sciences at ATSDR. He received his MSc from Fluminense Federal University, his MD from Petropolis Medical School, and his PhD from Sao Paulo University, all in Brazil. Kevin Horton is chief of the Environmental Health Surveillance Branch within the Division of Toxicology and Human Health Sciences at ATSDR. He holds a BA from Emory University, an MSPH from Tulane University School of Public Health and Tropical Medicine, and a DrPH from the University of Georgia’s College of Public Health.

Amyotrophic lateral sclerosis (ALS) is a progressive and often fatal neuromuscular disease. Most people die within 2–5 years of being diagnosed with ALS (Mitsumoto, Chad, & Pioro, 1998). Community concerns about perceived clusters of cases of ALS have challenged public health agencies to consider the possible contribution of environmental contaminants to the development of this disease. The general categories of possible environmental risk factors that have been investigated include heavy metals, trace elements, solvents and other volatile organic chemicals, ionizing and non-ionizing radiation, and agricultural chemicals.

Several investigations have been conducted of heavy metal exposure, particularly lead, as a risk factor for ALS. Some case-control studies demonstrated a positive association between past exposure to lead and risk of ALS (Armon, Kurland, Daube, & O’Brien, 1991; Kamel et al., 2002; Roelofs-Iverson, Mulder, Elveback, Kurland, & Molgaard, 1984). Also, the epidemiologic literature offers some support for an association between ALS and past exposure to organic solvents (Gunnarsson, Lindberg, Soderfeldt, & Axelson, 1991; McGuire et al., 1997).

In addition, certain occupations, such as military work, have been listed as a risk factor for ALS (Nicholas et al., 1998; Schulte, Burnett, Boeniger, & Johnson, 1996; Sutedja et al., 2009; Weisskopf et al., 2005). Several other potential risk factors have been evaluated in the scientific literature including infectious agents (Fang et al., 2011), nutritional intake (Okamoto, Kihira, Kohashi et al., 2009; Wang et al., 2011; Woolsey, 2008), physical activity, and trauma (Beghi et al., 2010; Okamoto, Kihira, Kondo et al., 2009; Piazza, Siren, & Ehrenreich, 2004; Strickland, Smith, Dolill, Goldman, & Roelofs, 1996).
Advancement of the Practice

Fall of 2010, uses a secure web portal to capture a major source of case ascertainment.

The ALS Registry is the first national surveillance project developed through the pilot projects. The National ALS Registry uses existing administrative data as prevalent cases based on an algorithm developed by the U.S. and its potential risk factors. The first approaches would be needed, however, to identify a larger portion of individuals with ALS.

In 2009, ATSDR implemented the National ALS Registry using a two-pronged approach to better describe the epidemiology of ALS in the U.S. and its potential risk factors. The first approach uses existing national administrative databases, including Medicare, Medicaid, Veterans Health Administration, and Veterans Benefit Administration records to identify prevalent cases based on an algorithm developed through the pilot projects. The National ALS Registry is the first national surveillance system to use existing administrative data as a major source of case ascertainment.

The second approach, implemented in the fall of 2010, uses a secure web portal to capture cases not included in the national administrative databases. This approach allows patients to self-identify and enroll in the ALS registry and take risk factor surveys. Current risk factor surveys include sociodemographic characteristics, occupational history (most recent and longest held jobs), military history, cigarette smoking, alcohol consumption, physical activity, family history of neurodegenerative diseases, and disease progression. In the near future, ATSDR expects to include additional surveys on residential history, pesticide exposures, occupations and hobbies involving toxic exposures, trauma (e.g., traumatic brain injury and electrical shocks), caffeine consumption, reproductive history, and health insurance information.

In addition, ATSDR is concurrently implementing surveillance activities that will allow for timely population-based case estimates of ALS in smaller defined geographic areas (i.e., at the state and metropolitan levels). Currently, Texas, Florida, New Jersey, Philadelphia, Chicago, Atlanta, Detroit, Los Angeles, and San Francisco are participating. These local surveillance activities will actively identify neurologists who diagnose or provide care for persons with ALS and check their medical records to find possible cases of ALS that have not been reported to the registry. This process will help ATSDR evaluate the registry’s completeness by comparing state and local data to data from the same areas collected in the registry. If some areas or groups are not well represented in the registry, ATSDR will find ways to reach these populations.

ATSDR is also developing a system to inform persons with ALS about new research studies. When researchers send ATSDR information about their studies, ATSDR will verify that the study has been approved by the researcher’s institutional review board. Then the agency will e-mail information about the study to registrants who have agreed to be contacted about such projects. Registrants will have to contact the researcher if they want to be in the study.

Finally, ATSDR is funding a feasibility study for the creation of a national bank of biological specimens—blood, saliva, and tissue—known as a bioregistry. These samples would come from people in the ALS registry. Linking the specimens to the information collected from registry participants will make the registry even more useful.

Many environmental causes have been implicated as the etiology of ALS. This disease, however, remains without a definite etiology. Moreover, the true burden of ALS is not known in the U.S. The National ALS Registry is responding to these scientific gaps by collecting nationwide data on disease prevalence, assessing risk factors for the development of ALS, and exploring ways of facilitating research on ALS. The registry web portal can be accessed at www.cdc.gov/als.

Corresponding Author: Vinicius C. Antao, Leader, Registries Team, Environmental Health Surveillance Branch, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 4770 Buford Highway, Mailstop F-57, Atlanta, GA 30341-3717. E-mail: VAntao@cdc.gov.

References


The uncertainty about the incidence and prevalence of ALS, as well as the lack of knowledge about the role of environmental exposures in the etiology of ALS, has created a need for structured data collection. In 2008, President Bush signed the ALS Registry Act into law, allowing the Agency for Toxic Substances and Disease Registry (ATSDR) to create the National ALS Registry. The purpose of the registry is to quantify the incidence and prevalence of ALS in the U.S., describe the demographics of persons with ALS, and examine risk factors for the disease.

When the law was enacted, ATSDR was already conducting four pilot projects (during 2006–2009) to determine the feasibility of creating a National ALS Registry. Results from these pilot projects showed that approximately 80% of ALS patients could be found through existing national databases. Combined methodologies would be needed, however, to identify a larger portion of individuals with ALS.

In 2009, ATSDR implemented the National ALS Registry using a two-pronged approach to better describe the epidemiology of ALS in the U.S. and its potential risk factors. The first approach uses existing national administrative databases, including Medicare, Medicaid, Veterans Health Administration, and Veterans Benefit Administration records to identify prevalent cases based on an algorithm developed through the pilot projects. The National ALS Registry is the first national surveillance system to use existing administrative data as a major source of case ascertainment.

The second approach, implemented in the fall of 2010, uses a secure web portal to capture cases not included in the national administrative databases. This approach allows patients to self-identify and enroll in the ALS registry and take risk factor surveys. Current risk factor surveys include sociodemographic characteristics, occupational history (most recent and longest held jobs), military history, cigarette smoking, alcohol consumption, physical activity, family history of neurodegenerative diseases, and disease progression. In the near future, ATSDR expects to include additional surveys on residential history, pesticide exposures, occupations and hobbies involving toxic exposures, trauma (e.g., traumatic brain injury and electrical shocks), caffeine consumption, reproductive history, and health insurance information.

In addition, ATSDR is concurrently implementing surveillance activities that will allow for timely population-based case estimates of ALS in smaller defined geographic areas (i.e., at the state and metropolitan levels). Currently, Texas, Florida, New Jersey, Philadelphia, Chicago, Atlanta, Detroit, Los Angeles, and San Francisco are participating. These local surveillance activities will actively identify neurologists who diagnose or provide care for persons with ALS and check their medical records to find possible cases of ALS that have not been reported to the registry. This process will help ATSDR evaluate the registry’s completeness by comparing state and local data to data from the same areas collected in the registry. If some areas or groups are not well represented in the registry, ATSDR will find ways to reach these populations.

ATSDR is also developing a system to inform persons with ALS about new research studies. When researchers send ATSDR information about their studies, ATSDR will verify that the study has been approved by the researcher’s institutional review board. Then the agency will e-mail information about the study to registrants who have agreed to be contacted about such projects. Registrants will have to contact the researcher if they want to be in the study.

Finally, ATSDR is funding a feasibility study for the creation of a national bank of biological specimens—blood, saliva, and tissue—known as a bioregistry. These samples would come from people in the ALS registry. Linking the specimens to the information collected from registry participants will make the registry even more useful.

Many environmental causes have been implicated as the etiology of ALS. This disease, however, remains without a definite etiology. Moreover, the true burden of ALS is not known in the U.S. The National ALS Registry is responding to these scientific gaps by collecting nationwide data on disease prevalence, assessing risk factors for the development of ALS, and exploring ways of facilitating research on ALS. The registry web portal can be accessed at www.cdc.gov/als.

Corresponding Author: Vinicius C. Antao, Leader, Registries Team, Environmental Health Surveillance Branch, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 4770 Buford Highway, Mailstop F-57, Atlanta, GA 30341-3717. E-mail: VAntao@cdc.gov.
References continued from page 29

commercial pilots and navigators. Journal of Occupational and Environmental Medicine, 40(11), 980–985.